Gilead (GILD) officer adds RSUs, 35,880 stock options in Form 4

Rhea-AI Filing Summary

Gilead Sciences’ Chief Comm & Corp Aff Officer Johanna Mercier reported routine equity compensation activity. She exercised 6,617 restricted stock units into the same number of common shares, with 3,216 shares withheld at a price of 148.5600 per share to cover tax obligations, leaving her with 134,779 common shares held directly.

Mercier also received new awards: 9,590 restricted stock units and 35,880 non-qualified stock options exercisable at 148.5600 per share and expiring on March 10, 2036. Both the RSUs and options vest over four years, with 25% vesting after one year and the remainder vesting 6.25% quarterly.

Insider Trade Summary

6,617 shares exercised/converted

Mixed 5 txns

Insider Mercier Johanna

Role Chief Comm & Corp Aff Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	6,617	$0.00	--
Grant/Award	Restricted Stock Unit	9,590	$0.00	--
Grant/Award	Non-qualified Stock Option (Right to Buy)	35,880	$0.00	--
Exercise	Common Stock	6,617	$0.00	--
Tax Withholding	Common Stock	3,216	$148.56	$478K

Holdings After Transaction: Restricted Stock Unit — 21,057 shares (Direct); Non-qualified Stock Option (Right to Buy) — 35,880 shares (Direct); Common Stock — 137,995 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. The stock options have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mercier Johanna

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Comm & Corp Aff Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		M		6,617	A	(1)	137,995	D
Common Stock	03/10/2026		F		3,216	D	$148.56	134,779	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/10/2026		M			6,617	(2)	(2)	Common Stock	6,617	(1)	21,057	D
Restricted Stock Unit	(1)	03/10/2026		A		9,590		(2)	(2)	Common Stock	9,590	(1)	30,647	D
Non-qualified Stock Option (Right to Buy)	$148.56	03/10/2026		A		35,880		(3)	03/10/2036	Common Stock	35,880	$0	35,880	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

3. The stock options have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Amy Kim by Power of Attorney for Johanna Mercier	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Johanna Mercier report at Gilead Sciences (GILD)?

Johanna Mercier reported routine equity compensation transactions. She exercised 6,617 restricted stock units into common shares, had 3,216 shares withheld for taxes, and received new grants of 9,590 restricted stock units plus 35,880 stock options at an exercise price of 148.5600.

How many Gilead (GILD) shares does Johanna Mercier hold after these Form 4 transactions?

After these transactions, Johanna Mercier directly holds 134,779 shares of Gilead common stock. This reflects the exercise of 6,617 restricted stock units and the withholding of 3,216 shares to satisfy tax obligations related to the vesting event reported on March 10, 2026.

What new equity awards did Johanna Mercier receive from Gilead Sciences (GILD)?

Johanna Mercier received 9,590 restricted stock units and 35,880 non-qualified stock options. The options have an exercise price of 148.5600 per share and expire on March 10, 2036, providing long-term incentive exposure to Gilead’s common stock.

What are the vesting terms of Johanna Mercier’s new Gilead (GILD) RSUs and options?

Both the RSUs and options follow a four-year vesting schedule. According to the disclosure, 25% vest on the first anniversary of the grant date, and the remaining 75% vest in 6.25% quarterly installments until fully vested over the four-year period.

Was Johanna Mercier’s Form 4 at Gilead (GILD) an open-market stock sale?

The Form 4 does not report any open-market sale. Instead, 3,216 shares of common stock were disposed of under code F, meaning they were withheld by the company to pay tax liabilities related to the equity vesting, not sold in the market.